Bio-Rad Labs (BIO): Raising PT On Multi Year Opportunity - Jefferies

September 7, 2016 7:47 AM EDT
Get Alerts BIO Hot Sheet
Price: $178.17 +0.80%

Rating Summary:
    4 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade BIO Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Brandon Couillard, reiterated his Buy rating on shares of Bio-Rad Labs (NYSE: BIO) as trough valuation on trough earnings leads the analyst to believe that BIO is the most under-appreciated asset in his universe.

The analyst believes that after the migration to a single global ERP is complete, BIO will be on the cusp of a profit margin & ROIC inflection point to a base case of >$10 of EPS power in 2020. Expectations are low & the path to structurally higher FCF/ROIC seems increasingly plausible.

The price target goes to $225 from $200.

For an analyst ratings summary and ratings history on Bio-Rad Labs click here. For more ratings news on Bio-Rad Labs click here.

Shares of Bio-Rad Labs closed at $151.66 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, Earnings

Add Your Comment